Eli Lilly stock gains from GLP-1 drug sales surge
Statements (64)
- Bullish
Eli Lilly is likely to see its stock price rise due to the signing of a $100 million research agreement with InnoCare.
- Bullish
Eli Lilly's stock price is likely to rise after its quarterly earnings beat estimates, as Wall Street's biggest bank identifies the selloff as a compelling entry point.
- Bullish
Eli Lilly's stock price could rise significantly if investors recognize the revenue growth disconnect as a sign of future profitability.
- Bearish
Eli Lilly stock slipped during the same capital markets day.
- Bullish
Eli Lilly stock fair value edges higher as analysts back GLP 1 growth
- Bullish
Lilly is reporting a near 300% rally in its stock price
- Bullish
Eli Lilly is receiving positive market reaction to a trend
- Bullish
Eli Lilly is selling 10 shares at roughly $1,269 each.
- Bullish
Eli Lilly is likely to see its stock price rise significantly following the announcement of a five-fold profit on one of its drug stock rallies.
- Bullish
Alzheimer's drug deal between Eli Lilly and AlzeCure Pharma may lead to increased demand for Alzheimer's treatments, potentially boosting Eli Lilly's stock price.
- Bullish
Eli Lilly is likely to see significant positive market reaction due to its reported 48% revenue growth in the second quarter, supported by UK regulatory approval, a new Medicare access program, and a pipeline addition.
- Bullish
Eli Lilly's stock is likely to rise following its strong quarterly earnings report that places it within a new buy point.
- Bullish
Eli Lilly is within striking distance of a new buy point following a strong quarterly earnings report
- Bullish
Eli Lilly stock climbed 9.86% in the past week
- Bullish
Eli Lilly is likely to see further price appreciation as it raises guidance following a strong quarter with revenue growth and EPS beat.
- Bullish
Eli Lilly is likely to see increased demand for its Foundayo weight-loss pill as it receives regulatory approval in the U.K.
- Bullish
Eli Lilly raised its full-year sales and profit targets following the quarter results
- Bullish
Eli Lilly is likely to see its stock price rise as it raises its full-year sales and profit targets following a quarter with $23.0 billion revenue.
- Bullish
Eli Lilly reported second-quarter revenue of $23.0 billion, up 48% from a year earlier
- Bullish
Eli Lilly's Q2 revenue growth of 47.7% year on year and full-year guidance exceeding analyst estimates are likely to drive upward pressure on its stock price due to improved market expectations.
- Bullish
Eli Lilly and Company is likely to see its stock price rise following its Q2 2026 earnings report showing 48% year-over-year revenue growth.
- Bullish
Eli Lilly is likely to see increased investor confidence and stock price appreciation following its strong financial performance and Morgan Stanley's positive outlook.
- Bullish
Eli Lilly is a healthcare stock to buy
- Bullish
Eli Lilly is likely to see its stock price rise as the company raises its full-year guidance following a beat-and-raise quarter.
- Bullish
Eli Lilly shares are likely to continue rising following its strong Q2 earnings report that highlighted nearly limitless demand for its weight-loss drug.
- Bullish
Eli Lilly's Zepbound and Mounjaro injectable weight-loss and diabetes drugs sales surged during the second quarter
- Bullish
Eli Lilly's Zepbound and Mounjaro sales surge likely to boost its stock price due to exceeding Wall Street estimates and widening the gap with Novo Nordisk.
- Bullish
Eli Lilly stock jumped as much as 7% on Wednesday
- Neutral
Eli Lilly expects revenue to fall between $85 billion and $87 billion for the year
- Bullish
Eli Lilly stock jumped as much as 7% on Wednesday
- Bullish
Eli Lilly is likely to see further stock gains as its 2026 sales forecast is raised due to strong demand for GLP-1 drugs.
- Bullish
Eli Lilly is likely to see further stock price increases as its 2026 sales forecast is raised due to strong demand for GLP-1 drugs.
- Bullish
Eli Lilly raised its 2026 sales forecast after seeing strong demand for GLP-1 drugs in its fiscal second quarter
- Neutral
Eli Lilly expects revenue to fall between $85 billion and $87 billion for the year
- Bullish
Eli Lilly raised its 2026 sales forecast after seeing strong demand for GLP-1 drugs in its fiscal second quarter
- Bullish
Eli Lilly reported record-breaking Q2 revenue driven by GLP-1 drugs
- Bullish
Eli Lilly is likely to see positive market reaction due to its record-breaking Q2 driven by GLP-1 drugs, with AI being the future focus.
- Bullish
Eli Lilly is likely to see further gains as its Q2 revenue exceeds analyst estimates, driven by volume growth outpacing price declines.
- Bullish
Eli Lilly and Company posted second-quarter revenue of $22.97 billion, up 48% year over year.
- Bullish
Eli Lilly is likely to see continued stock price appreciation due to strong Q2 earnings driven by demand for Zepbound and Mounjaro.
- Bullish
Eli Lilly shares are likely to continue rising as the company reported second quarter results that topped Wall Street revenue expectations and raised its full-year 2026 revenue outlook.
- Bullish
Eli Lilly is likely to see significant price increases due to strong sales of diabetes and obesity drugs exceeding expectations.
- Bullish
Eli Lilly & Co. is likely to see its stock price rise due to a 48% jump in second-quarter sales driven by surging demand for GLP-1 medications.
- Bullish
Eli Lilly is likely to see its stock price rise due to its Q2 2026 earnings beat and raised full-year revenue forecast.
- Bullish
Eli Lilly reported higher net income and revenue in the recent quarter
- Bullish
Eli Lilly reported higher revenue driven by continued demand for GLP-1 weight-loss drugs
- Bullish
Eli Lilly is likely to see its stock price rise due to higher revenue and net income driven by continued demand for GLP-1 drugs.
- Bullish
Eli Lilly stock jumped following a positive earnings report
- Bullish
Eli Lilly is up
- Bullish
Eli Lilly is likely to see its stock price rise significantly due to its Q2 revenue surge of 48% to $23 billion.
- Bullish
Eli Lilly is likely to see its stock price rise significantly due to its Q2 earnings exceeding estimates and increased demand for Zepbound and Mounjaro.
- Bullish
Eli Lilly raised its full-year sales outlook
- Bullish
Eli Lilly is likely to see continued market appreciation due to upcoming major catalysts announced in the article.
- Bullish
Eli Lilly is up 7% in 2026 compared to the overall stock market.
- Bullish
Eli Lilly is ripe for a stock split following a drug-fueled rally driven by obesity treatments
- Bullish
Eli Lilly is likely to see increased demand for its drug pipeline products following the FDA's breakthrough therapy designation for olomorasib.
- Bullish
Eli Lilly is likely to see increased demand for its pancreatic cancer treatment as it receives breakthrough status from the FDA.
- Bullish
Eli Lilly is likely to see significant positive market reaction due to its projected $2 trillion valuation target by 2031, which could attract institutional investors and boost stock prices.
- Bullish
Eli Lilly stock has skyrocketed
- Bullish
Loblaw's share price is likely to rise as it reports a 40% year-to-date increase in generic GLP-1 drug sales.
- Bullish
Eli Lilly is investing $2.8 billion in a new project beyond GLP-1 drugs
- Bearish
Goldman Sachs sees writing on the wall for Eli Lilly stock
- Bearish
Goldman Sachs sees writing on the wall for Eli Lilly stock
- Bullish
Eli Lilly is likely to see significant positive market reaction due to its revenue growth and FDA approval of Foundayo.